+22 C°
Traffic jam:   6

Johnson & Johnson has published report and annual forecast

21 April 2021
2 min.
Johnson & Johnson has published report and annual forecast

Report from J&J

J&J shares rose on Tuesday on the back of a financial report above Wall Street estimates, a dividend hike and the annual financial outlook. J&J reported that sales of its COVID-19 vaccines reached $100m. Investors are assessing the potential impact of J&J's vaccine suspension in the US.

Shares in Johnson & Johnson (JNJ), which has shown a small rise of 7% over the past 12 months and 3.4% since the start of 2021, rose nearly 1% in early trading on Tuesday amid the release of first-quarter financial results.

Johnson & Johnson reported that its earnings per share rose 12.6% in the first three months of the year (compared with last year's figure) to $2.59.

J&J's total net income for the first quarter rose 6.9% to $6.2 billion.

The company's revenue rose 7.9% to $22.32 billion, also above average analyst expectations of $22.01 billion.

J&J's US sales rose 3.9% to $11.11bn, while international sales jumped 12.2% to $11.21bn.

Most of the sales growth came from J&J's medical devices and pharmaceuticals divisions: up 11% to $6.58bn and up 9.6% to $12.12bn respectively, as the company sold $100m worth of its COVID-19 vaccines and clinics renewed demand for medical devices.

J&J's worldwide consumer products (hygiene and beauty products) revenues fell 2.3% to $3.54bn, which the company attributed to contrasting comparisons with the same quarter last year, when pandemics and quarantine restrictions started and consumers massively inventoried its products.

Johnson & Johnson's annual forecasts

J&J expects annual earnings of $9.42 to $9.57 per share, up from the previous forecast of $9.40-$9.60 earnings per share. The annual earnings forecast rose from a range of $90.5bn to $91.7bn. $91.7bn to $90.6bn. $91.6bn, representing sales growth of about 9.3%.

In addition, J&J increased its quarterly dividend by $0.05 or almost 5% to $1.06 per share. J&J is known for increasing its dividend for 57 consecutive years, despite a series of crises over the years. That's why J&J stock is one of the top dividend stocks according to many investment companies.

In a separate press release on Tuesday, J&J said it had applied to the Indian regulatory authority for an additional local clinical trial of its coronavirus vaccine.

Companies1 in the news



Rating companies
56 Mention
55 Mention
52 Mention
51 Mention
Dow Jones
43 Mention
43 Mention
31 Mention


News from GlobalNY.biz is the freshest and most relevant information about high-profile events in the region. The task of the resource's news feed is to convey to readers with maximum accuracy and objectivity information about important events in business, politics, economy, healthcare, culture and other spheres of life in New York.
GlobalNY.biz news is a coverage of economic processes taking place in New York, the latest news of public life, incidents and an overview of political events. New York news is information about the activities of small and medium-sized businesses, the work of housing and communal services and utilities, the implementation of significant projects.
The site's journalists describe not only the life of the region, but also talk about the current state of the US economy. Everything you need to know about innovations in the field of industry and agriculture, economy and power is collected in the "News" section at GlobalNY.biz.
New York news quickly informs the reader, shows the real picture and opens up hot topics. Communication with government structures and business enables us to provide our readers with reliable, information-rich material. The main page of the portal contains the key news of New York!
Alena Potapova

Development Director